ELI LILLY AND COMPANY Defined Benefit Plan, Effect of One Percentage Point Decrease on Accumulated Postretirement Benefit Obligation
ELI LILLY AND COMPANY (LLY) reported Defined Benefit Plan, Effect of One Percentage Point Decrease on Accumulated Postretirement Benefit Obligation of $52.70 million for the 12-month period ending 2014-12-31, per its 10-K filed 2015-02-19.
Discontinued › Notes › Compensation Related Costs › Defined Benefit Plan › Defined Benefit Plan, Effect of One-Percentage-Point Change in Assumed Health Care Cost Trend Rate
us-gaap:DefinedBenefitPlanEffectOfOnePercentagePointDecreaseOnAccumulatedPostretirementBenefitObligation1 · last filed 2015-02-19
- ELI LILLY AND COMPANY defined benefit plan, effect of one percentage point decrease on accumulated postretirement benefit obligation for fiscal 2014 was $52.70M, a 64.65% decline from fiscal 2013.
- ELI LILLY AND COMPANY defined benefit plan, effect of one percentage point decrease on accumulated postretirement benefit obligation for fiscal 2013 was $149.10M, a 22.99% decline from fiscal 2012.
- ELI LILLY AND COMPANY defined benefit plan, effect of one percentage point decrease on accumulated postretirement benefit obligation for fiscal 2012 was $193.60M.
| Period end | Defined Benefit Plan, Effect of One Percentage Point Decrease on Accumulated Postretirement Benefit Obligation 12 month |
|---|---|
| 2014-12-31 | $52.70M 10-K · filed 2015-02-19 |
| 2013-12-31 | $149.10M 10-K · filed 2014-02-19 |
| 2012-12-31 | $193.60M 10-K · filed 2013-02-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Akari Therapeutics Plc (AKTX) | $1,527.991B | -47,921.42 | |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |